Clinical trials in diabetic nephropathy, septic acute kidney injury and focal segmental glomerulosclerosis have examined the direct targeting of TGF-β1 with disappointing results, highlighting the diversity and complexity of TGF-β1 signalling in renal fibrosis and inflammation. The gene discussed is TGFB1; the disease is urogenital neoplasm.